Immune Profile Differs During Symptom Flare, Free in IBS-D

This article originally appeared here.
Share this content:
Immune Profile Differs During Symptom Flare, Free in IBS-D
Immune Profile Differs During Symptom Flare, Free in IBS-D

MONDAY, June 26, 2017 (HealthDay News) -- For patients with irritable bowel syndrome with diarrhea (IBS-D), interferon-γ concentrations and THELPER cells are inhibited during symptom flare, according to a research letter published online June 10 in Gut.

Chris Mavrangelos, from the University of Adelaide in Australia, and colleagues conducted a longitudinal study of patients with IBS comparing immune function within patients when they were free of symptoms and when they experienced symptom flare. The authors enrolled 11 patients with long-standing IBS who completed a valid self-report Bowel Disease Questionnaire and donated venous blood samples when free of symptoms and when experiencing a self-reported symptom flare.

The researchers found that symptom scores were significantly higher when subjects had symptom flare compared with being symptom free. When subjects were grouped together or when stratified according to bowel habit, the immune profile did not differ between symptom-flare and symptom-free time points. When subjects were grouped together, cytokine secretion and proliferative capacity did not differ between symptom-free and symptom-flare time points. On stratification by bowel habit, in IBS-D subjects, both interferon-γ concentrations and THELPER proliferation were significantly reduced during symptom-flare versus symptom-free time points.

"In order to accurately characterize immune profiles in IBS, researchers should consistently provide information regarding IBS subtype and symptom profile at the time of tissue sampling," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

Osimertinib Tops Standard EGFR-TKI for EGFR NSCLC

Osimertinib Tops Standard EGFR-TKI for <i>EGFR</i>&#43; NSCLC

Significantly longer median progression-free survival for osimertinib in previously untreated NSCLC

Distinct Features for Drug Use-Related Endophthalmitis

Distinct Features for Drug Use-Related Endophthalmitis

Injection drug users have fewer comorbidities and more improvement in visual acuity after intervention

Dating Violence Victimization, Nonmedical Rx Med Use Linked

Dating Violence Victimization, Nonmedical Rx Med Use Linked

Nonmedical use of prescription drugs linked to dating violence for male, female high school students

is free, fast, and customized just for you!

Already a member?

Sign In Now »